Lincoln Pharmaceuticals Ltd (NSE:LINCOLN) Stock Price, Trades & News

Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of cardiac, diabetic, anti-malarial, anti-biotic, anti-fungal, cephalosporin, analgesics, anesthetics, anti-pyretic, GIT products, vitamin-minerals, and iron preparations. Some of the key brands through which the company markets its products are; Rhino, Binafin, Kezolin, Hepalin, Progut, and Vomistat among others. Geographically, it carries out sales in India and outside India; generating key revenue from outside India.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	54.72
Equity-to-Asset	0.85
Debt-to-Equity	0.01
Debt-to-EBITDA	0.03
Interest Coverage	81.37
Piotroski F-Score	7/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	7.47	Distress Grey Safe
Beneish M-Score	-2.29	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

5/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	9.9
	3-Year EBITDA Growth Rate	5.6
	3-Year EPS without NRI Growth Rate	8.2
	3-Year FCF Growth Rate	47.6
	3-Year Book Growth Rate	14.7

Momentum Rank

7/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	37.54
	9-Day RSI	46.76
	14-Day RSI	49.02
	3-1 Month Momentum %	-8.82
	6-1 Month Momentum %	-8.54
	12-1 Month Momentum %	7.15

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	5.25
	Quick Ratio	4.53
	Cash Ratio	2.18
	Days Inventory	89.17
	Days Sales Outstanding	87.21
	Days Payable	96.13

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Dividend Yield %	0.3
	Dividend Payout Ratio	0.04
	3-Year Dividend Growth Rate	6.3
	Forward Dividend Yield %	0.3
	5-Year Yield-on-Cost %	0.29
	Shareholder Yield %	0.22

Profitability Rank

8/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	52.91
	Operating Margin %	12.45
	Net Margin %	13.89
	EBITDA Margin %	20.71
	FCF Margin %	11.57
	OCF Margin %	15.32
	ROE %	13.49
	ROA %	11.38
	ROIC %	12.27
	3-Year ROIIC %	3.08
	ROC (Joel Greenblatt) %	37.47
	ROCE %	17.5
	Years of Profitability over Past 10-Year	10

GF Value Rank

7/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	12.78
	Forward PE Ratio	8.54
	PE Ratio without NRI	12.78
	Shiller PE Ratio	15.6
	Price-to-Owner-Earnings	12.45
	PEG Ratio	1.78
	PS Ratio	1.78
	PB Ratio	1.63
	Price-to-Tangible-Book	1.61
	Price-to-Free-Cash-Flow	15.35
	Price-to-Operating-Cash-Flow	11.59
	EV-to-EBIT	7.61
	EV-to-EBITDA	6.81
	EV-to-Revenue	1.41
	EV-to-FCF	12.39
	Price-to-GF-Value	0.85
	Price-to-Projected-FCF	0.94
	Price-to-Median-PS-Value	1.31
	Price-to-Peter-Lynch-Fair-Value	1.69
	Price-to-Graham-Number	0.99
	Price-to-Net-Current-Asset-Value	2.7
	Price-to-Net-Cash	11.14
	Earnings Yield (Greenblatt) %	13.15
	FCF Yield %	6.6
	Forward Rate of Return (Yacktman) %	11.16

GF Value™: ₹717.12

NSE:LINCOLN

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with LINCOLN. Try a 7-Day Free Trial to check it out.

Lincoln Pharmaceuticals Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Lincoln Pharmaceuticals Ltd Stock Events

Financials Calendars

Event	Date	Price (₹)
INR 1.800000 Cash Dividend	2026-09-11	In 10 days
INR 1.800000 Cash Dividend	2025-09-12	558.70 (+0.10%)
INR 1.800000 Cash Dividend	2024-09-13	771.70 (-1.69%)
0.2:1 Stock Split	2009-03-19	--

Show

Entries

Press Release

	Subject	Date
No Press Release

Articles on Lincoln Pharmaceuticals Ltd

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.